Zalevsky Jonathan 4

What Happened

• Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), sold 180 shares in an open-market transaction on 2026-02-18. The weighted average sale price was $73.00, for total proceeds of approximately $13,140.
• Per the filing footnote, the sale was made to cover required tax withholding on vested RSUs and was not a discretionary trade by the reporting person.

Key Details

• Transaction date: 2026-02-18; Filing date: 2026-02-20 (Form 4 accession 0001193125-26-061886).
• Price(s): weighted average $73.00; executed in multiple trades at prices ranging $72.51–$74.00 (footnote).
• Shares sold: 180; Proceeds: ~$13,140.
• Shares owned after transaction: not disclosed in the Form 4 filing.
• Notable footnotes: F1 — sale to cover tax withholding on RSU vesting (not discretionary). F2 — multiple trades; reporting person will provide full trade-level details on request to SEC staff, issuer, or a security holder.
• Transaction code: S (Sale); the sale was for tax withholding related to an award (commonly reported as tax withholding/settlement).

Context

• Tax-withholding sales to cover RSU vesting are routine administrative transactions and do not necessarily indicate a change in executive sentiment about the company. Purchases typically give stronger signals about insider confidence than sales made for tax or payroll reasons.